Lungs News and Research

RSS

Broken heart syndrome may protect the heart from adrenaline overload

A condition that temporarily causes heart failure in people who experience severe stress might actually protect the heart from very high levels of adrenaline, according to a new study published in the journal Circulation. The research provides the first physiological explanation for Takotsubo cardiomyopathy, also called "broken heart syndrome" because it affects people who suffer severe emotional stress after bereavement, and suggests guidance for treatment.

27 Jun 2012

Scientists discover new flu-fighting role for IL-15 protein

University of Georgia scientists have discovered a new flu-fighting role for a well-known component of the immune system. Kimberly Klonowski, assistant professor of cellular biology in the UGA Franklin College of Arts and Sciences, and her colleagues found that administering a cell-signaling protein known as IL-15 to mice infected with influenza reduces their peak viral load by nearly three times.

27 Jun 2012

Heavily congested highway correlates with higher rates of asthma

Researchers at SUNY Downstate Medical Center and Lutheran Medical Center in Brooklyn, New York, found that living near a heavily congested highway correlates with a higher presence of asthma.

27 Jun 2012

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.

27 Jun 2012

New FIRS data reveals lack of understanding and concern among public about lung disease

New data released by the Forum of International Respiratory Societies (FIRS) to coincide with World Spirometry Day today has revealed a lack of understanding and concern among the public about the world's biggest killer - lung disease, which now claims the lives of almost 4 million people a year.

27 Jun 2012

Nanoparticles that can slip through mucus barriers shown to protect against herpes infections

Johns Hopkins researchers say they have demonstrated, for the first time in animals, that nanoparticles can slip through mucus to deliver drugs directly to tissue surfaces in need of protection. The researchers used these mucus-penetrating particles (MPPs) to protect against vaginal herpes infections in mice and the goal is to create similar MPPs to deliver drugs that protect humans against sexually transmitted diseases or even treat cancer.

26 Jun 2012

Experimental medication increases muscle strength in cancer patients with low testosterone levels

An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

LLUMC suggests check list with six key attributes for successful proton therapy treatment

When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.

26 Jun 2012

KaloBios’ KB001 shows promise against Pa pneumonia

Phase 2a trial results with KB001 suggest the recombinant, human PEGylated monoclonal antibody fragment, under development by KaloBios Pharmaceuticals, Inc. and Sanofi Pasteur, offers potential as an alternative to antibiotics for preventing or reducing pneumonias in mechanically ventilated intensive care unit (ICU) patients heavily colonized with Pseudomonas aeruginosa (Pa).

26 Jun 2012

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer.

26 Jun 2012

Ozone exposure associated with cardiovascular ailments

Young, healthy adult volunteers exposed for two hours to ozone developed physiological changes associated with cardiovascular ailments, according to a small study reported in Circulation, an American Heart Association journal.

26 Jun 2012

Riverain's ClearRead Bone Suppression software improves detection of lung cancer

Software by Riverain Technologies significantly improves radiologists' ability to detect potentially cancerous lung nodules in X-ray images, and might be a cost-effective alternative to dual energy subtraction (DES) imaging, according to two new studies being presented at the 20th Anniversary Meeting of the European Society of Thoracic Imaging (ESTI), June 22-24, in London.

23 Jun 2012

EMA CHMP adopts positive opinion for Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri Breezhaler (glycopyrronium/NVA237) 44 mcg delivered dose (50 mcg glycopyrronium per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

23 Jun 2012

IASLC to host 5th Latin American Conference on Lung Cancer in Brazil

The International Association for the Study of Lung Cancer (IASLC) is hosting the 5th Latin American Conference on Lung Cancer July 25 to 27 in Rio de Janeiro, Brazil. Nearly 1,000 medical professionals will gather to discuss the latest lung cancer research and treatment.

23 Jun 2012

Wake Forest Baptist researchers achieve early milestone in lab-engineered kidney project

Regenerative medicine researchers at Wake Forest Baptist Medical Center have reached an early milestone in a long-term project that aims to build replacement kidneys in the lab to help solve the shortage of donor organs.

23 Jun 2012

ATS task force recommends annual lung cancer screening using LDCT

A lung screening and surveillance task force, established by the American Association for Thoracic Surgery (AATS) and led by medical professionals from Brigham and Women's Hospital (BWH), is strongly recommending new guidelines for lung cancer screening. The guidelines were published this week in the online edition of the Journal of Thoracic and Cardiovascular Surgery (JTCVS).

22 Jun 2012

Structured exercise programmes benefit lung transplant patients

Lung transplant patients who took part in a three-month structured exercise program when they were discharged from hospital improved their health-related quality of life and reduced their risk of cardiovascular problems.

22 Jun 2012

UC3M joins European research project on tuberculosis treatments

Scientists at the Carlos III University in Madrid (UC3M) are participating in a European research project designed to study tuberculosis treatments. The objective of the study is to improve diagnostic imaging technology in order to help develop new drugs to treat the disease.

22 Jun 2012

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

New signal transduction pathway might be fruitful target for cancer drugs

Researchers at the University of California, San Diego School of Medicine have uncovered a new signal transduction pathway specifically devoted to the regulation of alternative RNA splicing, a process that allows a single gene to produce or code multiple types of protein variants. The discovery, published in the June 27, 2012 issue of Molecular Cell, suggests the new pathway might be a fruitful target for new cancer drugs.

22 Jun 2012